Co-Diagnostics, Inc. (CODX) Stock Forecast
CODX analyst forecast
as of October 17, 2026- Analyst consensus
- Buy 4.00 / 5 from 1 analysts
- Price target
- $4.00 average of analyst targets
- Upside to target
- +511.6% from the latest close
- Next earnings
- November 12, 2026
- 52-week range
- $0.65 – $37.80
CODX analyst ratings
1 analystsNumber of analysts at each rating.
CODX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
CODX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$1.25 | −$1.25 | −$1.25 | −$4.66 | +73.2% | 1 |
| Current fiscal year (2026) | −$3.10 | −$3.10 | −$3.10 | −$35.25 | +91.2% | 1 |
| Next fiscal year (2027) | −$0.83 | −$0.83 | −$0.83 | −$13.50 | +11.1% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
CODX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $169,000 | $169,000 | $169,000 | +16.2% | 1 |
| Current fiscal year (2026) | $654,000 | $654,000 | $654,000 | +5.1% | 1 |
| Next fiscal year (2027) | $17.3M | $17.3M | $17.3M | +2,546.5% | 1 |
CODX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
CODX revenue: reported and forecast
CODX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$2.85 | −$3.30 | −$3.30 | −$3.30 | −$1.25 | −56.1% | 1 up · 0 down |
| Current fiscal year (2026) | −$12.15 | −$13.50 | −$13.50 | −$13.50 | −$3.10 | −74.5% | 1 up · 0 down |
| Next fiscal year (2027) | −$12.00 | −$12.00 | −$12.00 | −$12.00 | −$0.83 | −93.1% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
CODX earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; CODX beat in 7 of 12.
What analysts expect from CODX
1 analysts cover Co-Diagnostics; their consensus rating is buy (4.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $4.00, 511.6% above the latest close of $0.65. Analysts expect earnings of −$3.10 per share for 2026, +91.2% from a year earlier. For 2027 the average estimate is −$0.83 per share on revenue of $17.3 million. Co-Diagnostics beat the EPS estimate in 7 of the last 12 quarters.
Related: CODX income statement, CODX key metrics, CODX chart. See the CODX stock overview for the latest quote and news.
CODX forecast FAQ
What is Co-Diagnostics's price target?
The average analyst price target for Co-Diagnostics is $4.00, 511.6% above the latest close of $0.65.
Is Co-Diagnostics a buy, hold or sell?
Of 1 analysts covering Co-Diagnostics, 0 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Co-Diagnostics's EPS forecast?
Analysts forecast −$3.10 per share for 2026 (range −$3.10 to −$3.10); for 2027 the estimate is −$0.83.
What is Co-Diagnostics's revenue forecast?
The average revenue estimate for 2026 is $0.7 million, growth of 5.1%; for 2027 it is $17.3 million.
When does Co-Diagnostics report earnings?
Co-Diagnostics is expected to report results for the quarter ending September 30, 2026 on November 12, 2026.
Does Co-Diagnostics usually beat earnings estimates?
Co-Diagnostics reported EPS at or above the analyst estimate in 7 of the last 12 quarters.